Clinical Scorecard: Uterine Structure in Normogonadotropic Anovulation: A Comparative Analysis of Polycystic Ovary Syndrome and Hypothalamic-Pituitary-Ovarian Dysfunction

At a Glance

Key Highlights

• Women with normogonadotropic anovulation have significantly reduced uterine and endometrial measurements compared to healthy controls.
• PCOS patients show lower uterine length, height, and volume than HPOD patients, with thicker endometrium in hyperandrogenemic PCOS cases.
• Uterine and endometrial dimensions correlate negatively with AMH and FSH, and positively with estradiol, prolactin, and metabolic markers such as insulin resistance.

Guideline-Based Recommendations

Diagnosis

• Use two- and three-dimensional transvaginal ultrasonography to measure uterine length, width, height, volume, and endometrial thickness and volume.
• Assess clinical and biochemical parameters including AMH, FSH, estradiol, prolactin, 17-hydroxyprogesterone, fasting insulin, and insulin resistance to interpret uterine morphology.

Management

• Consider hormonal and metabolic status when evaluating uterine morphology in women with normogonadotropic anovulation.
• Address hyperandrogenemia in PCOS patients as it may influence endometrial thickness.

Monitoring & Follow-up

• Monitor uterine and endometrial dimensions as indicators of reproductive and endocrine-metabolic health.
• Evaluate changes in uterine morphology in response to treatment of hormonal or metabolic abnormalities.

Risks

• Abnormal uterine and endometrial dimensions may impair fertility and pregnancy outcomes.
• Both hypoestrogenism and estrogen-progesterone imbalances can adversely affect uterine morphology and function.

Patient & Prescribing Data

Women with normogonadotropic anovulation including PCOS and HPOD aged 18-45

Uterine morphology reflects cumulative reproductive and metabolic influences; treatment should target hormonal and metabolic abnormalities to optimize uterine environment.

Clinical Best Practices

• Perform comprehensive ultrasonographic assessment of uterine and endometrial dimensions in women with menstrual irregularities.
• Integrate biochemical hormone and metabolic profiling to interpret uterine morphology accurately.
• Recognize the impact of hyperandrogenemia on endometrial thickness in PCOS patients.
• Use uterine measurements as part of fertility evaluation and management planning.
• Consider metabolic status and insulin resistance as factors influencing uterine and endometrial health.

References

• Ultrasonographic assessment of pelvic structures and uterine morphology
• PCOS and ovarian ultrasonographic criteria
• ClinicalTrials.gov Protocol Registration NCT06211608